Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting | ||
By: Nasdaq / GlobeNewswire - 11 Dec 2018 | Back to overview list |
|
EVANSTON, Ill., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced two upcoming poster presentations highlighting preclinical data on its novel NMDA receptor (NMDAr) modulator, NYX-2925, at the American College of Neuropsychopharmacology’s Annual Meeting in Hollywood, Florida. “We are encouraged by the preclinical effects we see with NYX-2925 on synaptic plasticity and sleep architecture, both of which are known to be NMDA receptor mediated,” said Joseph Moskal, Ph.D., chief scientific officer at Aptinyx. “These robust preclinical data advance our understanding of this novel mechanism of action and inform our confidence in NYX-2925 as we explore its potential as a treatment for chronic pain.” NYX-2925 is a novel NMDA receptor modulator currently in Phase 2 clinical development for the treatment of painful diabetic peripheral neuropathy (DPN) and under evaluation in an exploratory Phase 2 study in fibromyalgia. NYX-2925 has demonstrated robust activity in preclinical models of numerous neuropathic pain conditions with a favorable safety and tolerability profile. In a Phase 1 clinical study in healthy human subjects, NYX-2925 was well tolerated with no treatment related serious adverse events across a wide dose range, including dose levels well in excess of the expected therapeutic levels. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Aptinyx’s development of NYX-2925 for the treatment of neuropathic pain associated with DPN. Presentation Details: Presentation Title: NYX-2925 facilitates auditory-evoked long-term potentiation in rats: a translational approach for measuring NMDA receptor-mediated synaptic plasticity Presentation Title: Enhancement of synaptic plasticity by NYX-2925: Sleep cycle EEG studies in rats About Aptinyx Forward-Looking Statements Investor Contacts: Rachel Frank Media Contact: |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |